Interim report January-March 2013 A DIFFERENT KIND OF PHARMA COMPANY

Transcription

1 Interim report January-March 2013 A DIFFERENT KIND OF PHARMA COMPANY Press conference, May 21, 2013 at 10:00 a.m. (CET) Dial-in number: , enter code: Peter Wolpert, CEO and founder 0

2 Disclaimer Statements included herein that are not historical facts are forward-looking statements. Such forwardlooking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Moberg Pharma s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with the inherent uncertainty of pharmaceutical research and product development, manufacturing and commercialization, the impact of competitive products, patents, legal challenges, government regulation and approval, Moberg Pharma s ability to secure new products for commercialization and/or development and other risks and uncertainties detailed from time to time in Moberg Pharrma s interim or annual reports, prospectuses or press releases. 1 1

3 A different kind of pharma company Rapid growth under profitability with Nalox as key growth driver Products based on innovative drug delivery of proven molecules Direct sales in the U.S. Network of distributors/ partners in RoW Growth strategy Organic and M&A

4 First quarter highlights Continued strong topline growth Integration of acquired company successful Increased marketing activities and expanded distribution of Kerasal Nail Favorable opportunities for portfolio expansion Moberg Derma became Moberg Pharma Development of Limtop discontinued Agreement with Paladin Labs Inc. extended to Mexico 3 3

5 Sales increase owing to successful acquisition and strong organic growth Product Sales, all products 129% GROWTH IN PRODUCT SALES Q Q

6 Rapid growth in Nalox /Kerasal Nail sales and market share due to excellent distribution and successful marketing 46% GROWTH IN NALOX /KERASAL NAIL PRODUCT SALES Kerasal Nail U.S. market share Q Q

7 Continued strong growth, earnings affected by nonrecurring costs Jan-Mar Jan-Mar Full-year (MSEK) Revenues - Product Sales - Milestones EBITDA -2.2/0.9* /21.4* Operating profit -3.7/-0.6* /20.7* Earnings after Tax Earnings per Share (SEK) Cash position March * Excluding acquisition-related costs 6 6

8 41 percent of revenues from proprietary sales Distribution of revenue, Q Proprietary sales 41% Sales via distributors 59% Kerasal 24% JointFlex 12% Nalox/Keras al Nail 64% America 45% RoW 12% Europe 43% CHANNELS PRODUCTS GEOGRAPHY 7 7

9 Kerasal Nail rapidly gaining market share in the U.S. 5% 17% MARKET SHARE INCREASE LAST 12 MONTHS Available at 28,000 points of sale Distribution added through Duane Reade (N.Y.) and HEB (Texas) Sandal Season coming up marketing activities intensified 8 8

10 Continued international roll-out Nalox Now available in more than 25 markets Recently launched in Spain and Turkey Launch preparations at full intensity in Canada Agreement with Paladin expanded to Mexico Intensified marketing activities by partners over the March to October period Note: Not an all inclusive list. 9

11 Portfolio of growing brands Product Indication Market presence Nalox Kerasal Nail Kerasal JointFlex Damaged nails Dry cracked feet Joint and muscle pain Proprietary sales in the U.S. Launched by 10 partners in 25 markets Proprietary sales in the U.S. Launched by 13 partners in 15 markets Proprietary sales in the U.S. Launched by 14 partners in 20 markets 10 10

12 Organic growth >100 NEW BUSINESS OPPORTUNITIES TO BE EVALUTED 2013 Current products growing, line extensions Launches in new markets 8 patent families enable additional products - MOB Non-clinical programs Acquisitions/inlicensing Products - Focus on US OTC market Projects and technologies Interest areas for BD/Development: - Derma indications, e.g. Acne, Psoriasis, Pigmentation disorders - Select other indications 11 11

13 Strong financial position (MSEK) Mar 31, 2013 Mar 31, 2012 Dec 31, 2012 Assets Intangible fixed assets Tangible fixed assets Financial fixed assets Deferred tax assets Total fixed assets Inventories Accounts receivable and other receivables Cash and bank balances Total current assets TOTAL ASSETS Equity and liabilities Equity (attributable to Parent Company shareholders) Long term interest bearing liabilities Long term non interest bearing liabilities Current interest bearing liabilities Current non interest bearing liabilities TOTAL EQUITY AND LIABILITIES

14 Cash flow Jan Mar Jan Mar Full year (MSEK) Cash flow before changes in working capital Change in working capital CASH FLOW FROM OPERATING ACTIVITIES CASH FLOW FROM INVESTING ACTIVITIES CASH FLOW FROM FINANCING ACTIVITIES 0.0 Change in cash and cash equivalents Cash and cash equivalents at the start of the period Exchange rate difference for cash and cash equivalents 0.0 Cash and cash equivalents at the end of the period

15 Building A DIFFERENT KIND OF PHARMA COMPANY Excellent platform for further growth: rapidly increasing revenues profitability achieved ahead of plan U.S. sales & marketing organization Continued roll-out of Nalox and growth of Kerasal Nail Further exploitation of Kerasal & Jointflex MOB development & partnership Portfolio expansion through in-house projects, licensing and acquisitions 14 14